StockMarketWire.com - Futura Medical said a clinical trial of its erectile dysfunction treatment had not met its primary goals versus a placebo. The treatment, FM57, was compared to Futura's proprietary transdermal DermaSys formulation in the so-called phase three trial.

At 10:05am: [LON:FUM] Futura Medical PLC share price was -18.95p at 10.05p



Story provided by StockMarketWire.com